A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma

Munekage, Eri; Serada, Satoshi; Tsujii, Shigehiro; Yokota, Keiichiro; Kiuchi, Keita; Tominaga, Kenji; Fujimoto, Minoru; Kanda, Mizuki; Uemura, Sunao; Namikawa, Tsutomu; Nomura, Taisei; Murakami, Ichiro; Hanazaki, Kazuhiro; Naka, Tetsuji

doi:10.1016/j.neo.2021.07.006

Cited by 12 publications

(18 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this case, the specificity of an mAb is coupled with the toxicities of an anti-cancer drug to focus the activity of the drug at the tumor site. In this direction, two interesting preclinical studies were performed in PDAC and ESCC in-vitro and in-vivo models using an anti-GPC1 conjugated with monomethyl auristatin F and monomethyl auristatin E, respectively [ 98 , 108 ]. Both of the ADCs showed promising activity in-vitro and in the in-vivo models [ 98 , 108 ].…”

Section: Discussionmentioning

confidence: 99%

“…In this direction, two interesting preclinical studies were performed in PDAC and ESCC in-vitro and in-vivo models using an anti-GPC1 conjugated with monomethyl auristatin F and monomethyl auristatin E, respectively [ 98 , 108 ]. Both of the ADCs showed promising activity in-vitro and in the in-vivo models [ 98 , 108 ]. These results provide encouraging evidence for the set-up of an ADC recognizing GPC1 to be transferred to the clinical management of PDAC patients and others with GPC1-expressing tumors.…”

Section: Discussionmentioning

confidence: 99%

“…An antibody-drug conjugate (ADC) is a novel class of pharmacological compounds that take advantage of the specificity of an mAb to focus the toxicity of the anti-cancer drug at the tumor site [ 98 ]. The pioneer of ADC was the scientist Paul Ehrlich, who almost 100 years ago suggested the possibility of creating an antibody–toxin complex to improve toxin specificity [ 99 ].…”

Section: Targeting Strategiesmentioning

confidence: 99%

“…The ADC demonstrated anti-tumor activity in both the xenograft models and in the PDX, even if the anti-tumor activity is higher in the xenograft murine model, the levels of GPC1 being more homogeneous in comparison with the PDX model [ 108 ]. In 2021, Munekage and colleagues designated a novel ADC based on a humanized anti-GPC1 mAb bound to the monomethyl auristatin E (MMAE) [ 98 ]. This study reinforces the data from Nishigaki, showing a higher in-vitro antitumor activity of the ADC in GPC1-positive cell lines compared to those GPC1-negative [ 98 ].…”

Section: Targeting Strategiesmentioning

confidence: 99%

“…In 2021, Munekage and colleagues designated a novel ADC based on a humanized anti-GPC1 mAb bound to the monomethyl auristatin E (MMAE) [ 98 ]. This study reinforces the data from Nishigaki, showing a higher in-vitro antitumor activity of the ADC in GPC1-positive cell lines compared to those GPC1-negative [ 98 ]. The ADC also demonstrated high anti-tumor activity in the in-vivo xenograft models, in PDX murine models of PDAC, and in esophageal squamous cell carcinoma (ESCC) [ 98 ].…”

Section: Targeting Strategiesmentioning

confidence: 99%

See 4 more Smart Citations

The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma

Busato

Mossenta

et al. 2022

IJMS

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of all pancreatic cancers, with a 5-year survival rate of 7% and 80% of patients diagnosed with advanced or metastatic malignancies. Despite recent advances in diagnostic testing, surgical techniques, and systemic therapies, there remain limited options for the effective treatment of PDAC. There is an urgent need to develop targeted therapies that are able to differentiate between cancerous and non-cancerous cells to reduce side effects and better inhibit tumor growth. Antibody-targeted strategies are a potentially effective option for introducing innovative therapies. Antibody-based immunotherapies and antibody-conjugated nanoparticle-based targeted therapies with antibodies targeting specific tumor-associated antigens (TAA) can be proposed. In this context, glypican-1 (GPC1), which is highly expressed in PDAC and not expressed or expressed at very low levels in non-malignant lesions and healthy pancreatic tissues, is a useful TAA that can be achieved by a specific antibody-based immunotherapy and antibody-conjugated nanoparticle-based targeted therapy. In this review, we describe the main clinical features of PDAC. We propose the proteoglycan GPC1 as a useful TAA for PDAC-targeted therapies. We also provide a digression on the main developed approaches of antibody-based immunotherapy and antibody-conjugated nanoparticle-based targeted therapy, which can be used to target GPC1.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Targeting Strategiesmentioning

confidence: 99%

Section: Targeting Strategiesmentioning

confidence: 99%

Section: Targeting Strategiesmentioning

confidence: 99%

See 3 more Smart Citations

The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma

Busato

Mossenta

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

Integrating TCGA and single-cell sequencing data for colorectal cancer: a 10-gene prognostic risk assessment model

Lu,

Li,

Yuan

et al. 2023

Discov Onc

View full text Add to dashboard Cite

Colorectal cancer represents a significant health threat, yet a standardized method for early clinical assessment and prognosis remains elusive. This study sought to address this gap by using the Seurat package to analyze a single-cell sequencing dataset (GSE178318) of colorectal cancer, thereby identifying distinctive marker genes characterizing various cell subpopulations. Through CIBERSORT analysis of colorectal cancer data within The Cancer Genome Atlas (TCGA) database, significant differences existed in both cell subpopulations and prognostic values. Employing WGCNA, we pinpointed modules exhibiting strong correlations with these subpopulations, subsequently utilizing the survival package coxph to isolate genes within these modules. Further stratification of TCGA dataset based on these selected genes brought to light notable variations between subtypes. The prognostic relevance of these differentially expressed genes was rigorously assessed through survival analysis, with LASSO regression employed for modeling prognostic factors. Our resulting model, anchored by a 10-gene signature originating from these differentially expressed genes and LASSO regression, proved adept at accurately predicting clinical prognoses, even when tested against external datasets. Specifically, natural killer cells from the C7 subpopulation were found to bear significant associations with colorectal cancer survival and prognosis, as observed within the TCGA database. These findings underscore the promise of an integrated 10-gene signature prognostic risk assessment model, harmonizing single-cell sequencing insights with TCGA data, for effectively estimating the risk associated with colorectal cancer.

show abstract

Clinical toxicity of antibody–drug conjugates

Gupta,

Panchal,

Pawar

et al. 2024

Public Health and Toxicology Issues Drug Research, Volume 2

View full text Add to dashboard Cite

A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma

Cited by 12 publications

References 31 publications

The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma

The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma

Integrating TCGA and single-cell sequencing data for colorectal cancer: a 10-gene prognostic risk assessment model

Clinical toxicity of antibody–drug conjugates

Contact Info

Product

Resources

About